Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

Flor M. Muñoz(Johns Hopkins University), Lawrence Sher(Johns Hopkins University), Charu Sabharwal(Johns Hopkins University), Alejandra Gurtman(Johns Hopkins University), Xia Xu(Johns Hopkins University), Nicholas Kitchin(Johns Hopkins University), Stephen Lockhart(Johns Hopkins University), Robert Riesenberg(Johns Hopkins University), Joanna M Sexter(Johns Hopkins University), Hanna Czajka(Johns Hopkins University), Grant Paulsen(Johns Hopkins University), Yvonne Maldonado(Johns Hopkins University), Emmanuel B. Walter(Johns Hopkins University), Kawsar R. Talaat(Johns Hopkins University), Janet A. Englund(Johns Hopkins University), Uzma Sarwar(Johns Hopkins University), Caitlin E. Hansen(Johns Hopkins University), Martha Iwamoto(Johns Hopkins University), Chris Webber(Johns Hopkins University), Luke Cunliffe(Johns Hopkins University), Benita Ukkonen(Johns Hopkins University), Silvina N Martínez(Johns Hopkins University), Barbara Pahud(Johns Hopkins University), Iona Munjal(Johns Hopkins University), Joseph B. Domachowske(Johns Hopkins University), Kena A. Swanson(Johns Hopkins University), Hua Ma(Johns Hopkins University), Kenneth Koury(Johns Hopkins University), Susan Mather(Johns Hopkins University), Claire Lu(Johns Hopkins University), Jing Zou(Johns Hopkins University), Xuping Xie(Johns Hopkins University), Pei‐Yong Shi(Johns Hopkins University), David Cooper(Johns Hopkins University), Özlem Türeci(Johns Hopkins University), Uğur Şahin(Johns Hopkins University), Kathrin U. Jansen(Johns Hopkins University), William C. Gruber(Johns Hopkins University)
New England Journal of Medicine
February 15, 2023
10.1056/nejmoa2211031
Cited by 98Open Access
Full Text

Abstract

BACKGROUND: Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children. METHODS: We conducted a phase 1 dose-finding study and are conducting an ongoing phase 2-3 safety, immunogenicity, and efficacy trial of the BNT162b2 vaccine in healthy children 6 months to 11 years of age. We present results for children 6 months to less than 2 years of age and those 2 to 4 years of age through the data-cutoff dates (April 29, 2022, for safety and immunogenicity and June 17, 2022, for efficacy). In the phase 2-3 trial, participants were randomly assigned (in a 2:1 ratio) to receive two 3-μg doses of BNT162b2 or placebo. On the basis of preliminary immunogenicity results, a third 3-μg dose (≥8 weeks after dose 2) was administered starting in January 2022, which coincided with the emergence of the B.1.1.529 (omicron) variant. Immune responses at 1 month after doses 2 and 3 in children 6 months to less than 2 years of age and those 2 to 4 years of age were immunologically bridged to responses after dose 2 in persons 16 to 25 years of age who received 30 μg of BNT162b2 in the pivotal trial. RESULTS: During the phase 1 dose-finding study, two doses of BNT162b2 were administered 21 days apart to 16 children 6 months to less than 2 years of age (3-μg dose) and 48 children 2 to 4 years of age (3-μg or 10-μg dose). The 3-μg dose level was selected for the phase 2-3 trial; 1178 children 6 months to less than 2 years of age and 1835 children 2 to 4 years of age received BNT162b2, and 598 and 915, respectively, received placebo. Immunobridging success criteria for the geometric mean ratio and seroresponse at 1 month after dose 3 were met in both age groups. BNT162b2 reactogenicity events were mostly mild to moderate, with no grade 4 events. Low, similar incidences of fever were reported after receipt of BNT162b2 (7% among children 6 months to <2 years of age and 5% among those 2 to 4 years of age) and placebo (6 to 7% among children 6 months to <2 years of age and 4 to 5% among those 2 to 4 years of age). The observed overall vaccine efficacy against symptomatic Covid-19 in children 6 months to 4 years of age was 73.2% (95% confidence interval, 43.8 to 87.6) from 7 days after dose 3 (on the basis of 34 cases). CONCLUSIONS: A three-dose primary series of 3-μg BNT162b2 was safe, immunogenic, and efficacious in children 6 months to 4 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).

Related Papers

No related papers found

Powered by citation graph analysis